Every letter we have printed

The table showing what each method can detect is valuable but incomplete. You show no row for C-terminal truncation or N-terminal truncation as distinct phenomena. These are not rare, and they often elute differently depending on which end is missing. A generic gradient might resolve them; an improperly designed orthogonal method might not. The capability matrix should separate these cases.

A small technical correction. You write that trifluoroacetic acid is used at around 0.1 per cent. In peptide work concentrations of 0.05 to 0.1 per cent are both common, and some methods run higher for particularly basic sequences. The figure reads as though it were a standard rather than a range.

Nothing in a chromatogram addresses aggregation, and size-exclusion is the obvious complement rather than another reversed-phase run. It is a different question, a different column and a different afternoon, and for a peptide that has been through a freeze-thaw cycle it is frequently the more informative one.

Where a trial protocol specified a management approach, that fact belongs in any discussion of the trial’s tolerability results, because the results describe a managed population. It is usually in the methods and never in the summary.

Any strategy described in this context should be labelled with what supports it: a trial, an observational study, professional guidance, or nothing but practice. Four labels, applied honestly, would change how the whole subject reads.

I stopped at week six because I could not keep anything down for three days, and my prescriber told me I had not given it a fair chance. Reading your definition of dose-limiting, I think what happened was that nobody offered me the option of going back to the lower dose. It was escalate or stop.

Slower escalation as an alternative to stopping is the option that most often gets skipped, and the trial protocols permitted it. Presenting the choice as continue or stop leaves out the middle that the evidence base itself used.

What the single figure hides is the shape of what is left over. Ninety-eight per cent with one impurity at two is a different material from ninety-eight per cent with forty impurities at one twentieth each, and a buyer who cares about the second case is given no way to tell them apart.

You describe the settlement on a single metric as never having been argued for. It was argued for, quietly, by the people who had to price testing. When a determination costs a few tens of pounds and the alternative costs several hundred, the market does not deliberate; it economises. Your piece is right about the outcome and generous about the process.

A note on vocabulary from a reader who works with long-term conditions. In every other context, maintenance describes a phase of ongoing management with regular review. Here it is used to mean the part where nothing needs attention, which is close to the opposite.

The costs compound quietly. A monthly figure that seemed acceptable at the start becomes a substantial annual commitment, and almost nobody in the accounts I read did that arithmetic before beginning.

Your piece describes tapering as pharmacologically pointless and then spends three paragraphs making a case for it. Pick one.

Trend beats absolute value for almost everything in an organ panel, and a single report cannot show a trend. The most useful thing anybody can do is keep every result they have ever had in one place.

Muscle-derived enzymes appear in panels that are named for other organs, and any change in activity produces a change in them. It is the commonest benign explanation for a flagged result in an active population.

My eGFR has risen from 71 to 84 over fourteen months of treatment and I have lost twenty-six kilograms. My prescriber described this as the drug protecting my kidneys. Having read your creatinine section, I suspect it is mostly that I have less muscle. Which of us is right?

The test is destructive, which is the point your piece makes lightly and which deserves more weight. Every unit tested is a unit that cannot be sold, and on a small fill that is a real proportion of the batch. It is an argument for process assurance rather than for testing more.

The people best placed to change this are the testing services rather than the suppliers. A service that offered the determination as a standard part of its panel would create the expectation in one season.

The section on what the pharmacology does not tell us is the one I would keep if the rest were cut. Receptor occupancy does not predict a clinical response, and a mechanistic story that explains a result after the fact is not evidence that the result will generalise.

The limits of what receptor pharmacology can explain are worth stating explicitly in every piece of this kind. A mechanism can be entirely correct and still fail to predict an outcome, and this literature has several such cases.

Renal expression and the natriuretic findings deserve a paragraph, given how much interest there now is in kidney outcomes. It is a genuinely separate line of work from the metabolic one and it is developing quickly.

Gastric emptying delay is often treated as a side effect and it is at least partly a mechanism of the primary effect. That reframing changes how a reader should think about the management advice, and it is worth stating explicitly rather than leaving to be inferred.

Thank you for declining to tell readers what to do. The restraint is unusual and it is the reason I trust what you do print.

Baseline transit varies enormously across a healthy population and is almost never measured before the intervention. A study without baseline measurement is estimating a change from an assumed starting point.

The vagal afferent pathway is the part of the story with the strongest experimental support and the weakest presence in general discussion, presumably because it is harder to draw. Mechanistic coverage tends to follow what can be diagrammed.

Reported rates depend heavily on whether the study asked or waited to be told. Solicited and unsolicited adverse event collection produce different numbers from the same population, and the method is buried in the supplement.

Adding a second medicine to manage the effects of the first is a real decision with its own consequences, and it is discussed far too casually in general forums. It belongs with a clinician who knows the whole picture, and this letter is not advice to anyone.

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

An observation about self-selection in the accounts you print. People who write to a publication about stopping are people who thought about it enough to write. The quiet majority who simply stopped ordering are not represented and probably outnumber the correspondents considerably.

A reason absent from every list: the person stopped believing the material was what it claimed to be. In a market where that is a live question, it is an obvious category, and no clinical taxonomy would ever include it.

Vacuum in a lyophilised vial is a useful and under-used indicator. A vial stoppered under partial vacuum draws diluent in when the needle is inserted; one that does not has either lost its seal or was never stoppered under vacuum. Either answer is worth knowing before you use the contents.

Particulate matter deserves its own paragraph. Glass delamination, stopper fragments and fibres are all real findings in vialled products, and the only examination most buyers perform is a glance at a powder they cannot see through. Look again after reconstitution and against a dark background.

The most important sentence in this series is that a purity certificate is silent on microbiology. Chromatography reports on molecules and says nothing whatever about organisms or their fragments, and a great many buyers read a high purity figure as a general assurance of cleanliness. The document does not make that claim and cannot.

Comparison shopping in this market is conducted on price and purity, in that order, and both are single numbers. A market that compares on two scalars will not develop a third.

The duration after withdrawal is the parameter that determines the headline, and it varies between studies more than any other design feature. A curve measured to week twenty and a curve measured to week eighty tell very different stories about the same phenomenon.

The run-in period does a lot of work in these designs and is rarely described in coverage. Everybody in the randomised phase has already demonstrated tolerance and response, and the population is therefore selected before the interesting part begins.

The claim that stopping does not leave you worse off than baseline is a group-level claim about trial arms. Individuals can and do overshoot. Your phrasing invites readers to conclude otherwise.

Analytical quality matters more over a long horizon than a short one, which is a point this publication is well placed to make. A material used once is a single exposure; a material used for years is a cumulative one, and the standard a buyer applies should rise accordingly.

Custody matters most exactly when the result is bad, which is when nobody has a record. The discipline has to be in place before it is needed, and the incentive to establish it only appears afterwards.

The service could close half this gap by publishing a submission protocol and refusing samples that do not follow it. Refusal is the mechanism nobody wants to use, and it is the only one that changes behaviour.

Your series has not yet addressed what a buyer should do with a single blind result that disagrees with a supplier’s certificate. The honest answer is very little, and saying so would be more useful than another round of methodological argument.